BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 11160356)

  • 1. Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes.
    Kawakami Y; Wang X; Shofuda T; Sumimoto H; Tupesis J; Fitzgerald E; Rosenberg S
    J Immunol; 2001 Feb; 166(4):2871-7. PubMed ID: 11160356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes.
    Benlalam H; Linard B; Guilloux Y; Moreau-Aubry A; Derré L; Diez E; Dreno B; Jotereau F; Labarrière N
    J Immunol; 2003 Dec; 171(11):6283-9. PubMed ID: 14634146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of an in vitro immunoselected tumor line to identify shared melanoma antigens recognized by HLA-A*0201-restricted T cells.
    Harada M; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
    Cancer Res; 2001 Feb; 61(3):1089-94. PubMed ID: 11221837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
    Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
    J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen.
    Novellino L; Renkvist N; Rini F; Mazzocchi A; Rivoltini L; Greco A; Deho P; Squarcina P; Robbins PF; Parmiani G; Castelli C
    J Immunol; 2003 Jun; 170(12):6363-70. PubMed ID: 12794170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
    Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
    J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.
    Schneider J; Brichard V; Boon T; Meyer zum Büschenfelde KH; Wölfel T
    Int J Cancer; 1998 Jan; 75(3):451-8. PubMed ID: 9455808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition.
    Stevens EJ; Jacknin L; Robbins PF; Kawakami Y; el Gamil M; Rosenberg SA; Yannelli JR
    J Immunol; 1995 Jan; 154(2):762-71. PubMed ID: 7814882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of tumoricidal cytotoxic T lymphocytes from healthy donors after in vitro stimulation with a replication-incompetent vaccinia virus encoding MART-1/Melan-A 27-35 epitope.
    Zajac P; Oertli D; Spagnoli GC; Noppen C; Schaefer C; Heberer M; Marti WR
    Int J Cancer; 1997 May; 71(3):491-6. PubMed ID: 9139889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12.
    Panelli MC; Bettinotti MP; Lally K; Ohnmacht GA; Li Y; Robbins P; Riker A; Rosenberg SA; Marincola FM
    J Immunol; 2000 Apr; 164(8):4382-92. PubMed ID: 10754339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype.
    Sensi M; Nicolini G; Zanon M; Colombo C; Molla A; Bersani I; Lupetti R; Parmiani G; Anichini A
    Cancer Res; 2005 Jan; 65(2):632-40. PubMed ID: 15695408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion.
    Linard B; Bézieau S; Benlalam H; Labarrière N; Guilloux Y; Diez E; Jotereau F
    J Immunol; 2002 May; 168(9):4802-8. PubMed ID: 11971032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.
    Kawakami Y; Eliyahu S; Delgado CH; Robbins PF; Rivoltini L; Topalian SL; Miki T; Rosenberg SA
    Proc Natl Acad Sci U S A; 1994 Apr; 91(9):3515-9. PubMed ID: 8170938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma.
    Ayyoub M; Stevanovic S; Sahin U; Guillaume P; Servis C; Rimoldi D; Valmori D; Romero P; Cerottini JC; Rammensee HG; Pfreundschuh M; Speiser D; Lévy F
    J Immunol; 2002 Feb; 168(4):1717-22. PubMed ID: 11823502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
    Bettinotti MP; Kim CJ; Lee KH; Roden M; Cormier JN; Panelli M; Parker KK; Marincola FM
    J Immunol; 1998 Jul; 161(2):877-89. PubMed ID: 9670966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma.
    Rimoldi D; Rubio-Godoy V; Dutoit V; Lienard D; Salvi S; Guillaume P; Speiser D; Stockert E; Spagnoli G; Servis C; Cerottini JC; Lejeune F; Romero P; Valmori D
    J Immunol; 2000 Dec; 165(12):7253-61. PubMed ID: 11120859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
    Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.
    Kawakami Y; Eliyahu S; Delgado CH; Robbins PF; Sakaguchi K; Appella E; Yannelli JR; Adema GJ; Miki T; Rosenberg SA
    Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6458-62. PubMed ID: 8022805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor antigens isolated from a patient with vitiligo and T-cell-infiltrated melanoma.
    Kiniwa Y; Fujita T; Akada M; Ito K; Shofuda T; Suzuki Y; Yamamoto A; Saida T; Kawakami Y
    Cancer Res; 2001 Nov; 61(21):7900-7. PubMed ID: 11691810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes.
    Gaugler B; Van den Eynde B; van der Bruggen P; Romero P; Gaforio JJ; De Plaen E; Lethé B; Brasseur F; Boon T
    J Exp Med; 1994 Mar; 179(3):921-30. PubMed ID: 8113684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.